Ochre Bio inks billion-plus dollar deal with Boehringer

Oxford, UK-based start-up Ochre Bio, an innovator in chronic liver disease drug development, today announced a partnership with family-owned German pharma major Boehringer Ingelheim.

The collaboration is focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Ochre Bio says that it will utilize its proprietary discovery platform combining machine learning with human big data, including advanced imaging and deep genomic phenotyping, as well as in-house RNA chemistry, and the unique ability to employ proprietary ex-vivo human-organ perfusion models. This will enable the identification, characterization, and validation of multiple novel regenerative targets for CLDs.